This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Flector Patch 1.3%
Drug Names(s): Flector EP Tissugel, diclofenac hydroxyethylpyrrolidine (DHEP) and heparin sodium, diclofenac epolamine topical patch
Description: Flector EP Tissugel is a medicated plaster containing diclofenac hydroxyethylpyrrolidine (DHEP) 180 mg and heparin sodium 5,600 IU.
Alpharma and IBSA
On August 16, 2007, Alpharma (a division of Pfizer) announced it reached an agreement with Institut Biochimique SA (IBSA), to obtain exclusive license and distribution rights to market the Flector Patch, the first prescription topical NSAID (non-steroidal anti-inflammatory drug) patch approved by the FDA in the United States. IBSA will supply (through a third party manufacturer) the Flector Patch to Alpharma for the term of the agreement. In addition, under the terms of its agreements with IBSA, Alpharma will also receive exclusive U.S. license and distribution rights to Tirosint (synthetic levothyroxine sodium) gel capsules for thyroid hormone replacement therapy, recently approved by the FDA.
The terms of the agreements include a $100 million payment to be made at closing, warrants for the purchase of up to one million shares of the company's common stock at a price of $35 per share, as well as on-going consideration for supply of products.
Partners: Institut Biochimique SA
Flector Patch 1.3% News
Additional information available to subscribers only: